Corporate News
Invex Therapeutics Ltd (IXC.AX) reported a 24‑hour trading range that was flat, with the share price unchanged at approximately AUD 0.10. The stock closed at AUD 0.10 on Thursday, 22 October 2026, at 20:02 Central Europe time. During the period, trading volume was about AUD 4.6 k, which represents a very small fraction of the company’s total shares outstanding.
- Shares outstanding: 75.1 million.
- Market capitalization: AUD 7.9 million.
- Last 24‑hour volume: AUD 4.6 k.
- Monthly performance: down 8.7 % since the end of last month.
- 200‑day simple moving average: AUD 0.11.
- 52‑week high: AUD 0.15 (13 November 2025).
- 52‑week low: AUD 0.09 (1 July 2026).
Recent Corporate Actions
Banco Invex, acting as the trustee of the irrevocable investment trust linked to Invex Therapeutics, announced capital‑reimbursement distributions for multiple series of investment‑trust certificates. On 21 October 2026, the BMV issued notices for eight series (22‑2, 22‑3, 22‑4, 22‑5, 22‑6, 22‑7, 23‑3, 23‑5, 23‑6, and 23‑7). Each series is scheduled to pay on 29 October 2026. The distributions, which refund capital, involve between approximately 1 million and 2 million certificates per series and will be paid through Indeval.
In addition, Banco Invex disclosed a public offer for the reciprocal acquisition and subscription of real‑estate investment‑trust (FIBRA) certificates issued by the FIBRA MQ trust. The offer, starting 30 September 2026, allows holders of FIBRA MQ certificates to exchange them for FIBRA MTY certificates or cash. The proposal could involve up to about 475 million exchange certificates and a cash consideration of up to approximately 6.5 billion pesos. These actions are routine corporate‑finance activities and do not trigger immediate regulatory or tax implications beyond standard reporting requirements.
Comparable Stock Performance
| Ticker | 24‑hour change | Current price | Market cap |
|---|---|---|---|
| CAZ.AX | 0 % | AUD 0.02 | AUD 9.4 million |
| M96.AX | 0 % | AUD 0.00 | AUD 9.2 million |
| RLG.AX | 0 % | AUD 0.00 | AUD 9.3 million |
| AXR.AX | -6.06 % | AUD 0.16 | AUD 9.3 million |
| FNR.AX | 0 % | AUD 0.12 | AUD 9.3 million |
Company Background
Invex Therapeutics Ltd is an Australian biotechnology firm that develops therapeutic solutions for neurological conditions and head injuries. Its product portfolio focuses on disorders associated with raised intracranial pressure, idiopathic intracranial hypertension, and ruptured brain injuries. The company’s operations are confined to the Australian market.
